JOHNSON & JOHNSON ($JNJ)
Filing Information
| Accession Number | 0000200406-26-000039 |
|---|---|
| Form Type | 4 |
| Filing Date | Feb 19, 2026 |
| Document Date | Feb 15, 2026 |
| Document | View SEC Filing |
Transactions
15
Total Shares
217,460
Total Value
$21,430,784.22
P&L
+inf% (+$12,457,663.36)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP, Innovative Medicine, R&D | Common Stock | โ | Feb 15, 2026 | Exercise/Conversion | 1,349 | $0.00 | $0.00 | 12,007 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Common Stock | โ | Feb 15, 2026 | Tax Withholding | 385 | $243.45 | $93,728.25 | 11,622 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Common Stock | โ | Feb 15, 2026 | Exercise/Conversion | 1,847 | $0.00 | $0.00 | 13,469 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Common Stock | โ | Feb 15, 2026 | Tax Withholding | 528 | $243.45 | $128,541.60 | 12,941 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Common Stock | โ | Feb 17, 2026 | Exercise/Conversion | 21,721 | $157.92 | $3,430,180.32 | 34,662 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Common Stock | โ | Feb 17, 2026 | Sale | 21,721 | $243.00 | $5,278,203.00 | 12,941 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Common Stock | โ | Feb 17, 2026 | Exercise/Conversion | 29,927 | $156.15 | $4,673,101.05 | 42,868 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Common Stock | โ | Feb 17, 2026 | Sale | 29,927 | $243.00 | $7,272,261.00 | 12,941 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Common Stock | โ | Feb 17, 2026 | Sale | 2,283 | $243.00 | $554,769.00 | 10,658 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Restricted Share Units | Derivative | Feb 15, 2026 | Exercise/Conversion | 1,349 | $0.00 | $0.00 | 1,349 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Restricted Share Units | Derivative | Feb 15, 2026 | Exercise/Conversion | 1,847 | $0.00 | $0.00 | 3,692 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Employee Stock Options (Right to Buy) | Derivative | Feb 15, 2026 | Grant/Award | 49,382 | $0.00 | $0.00 | 49,382 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Restricted Share Units | Derivative | Feb 15, 2026 | Grant/Award | 3,546 | $0.00 | $0.00 | 3,546 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Employee Stock Options (Right to Buy) | Derivative | Feb 17, 2026 | Exercise/Conversion | 21,721 | $0.00 | $0.00 | 21,721 | Direct | โ | View Details | |
EVP, Innovative Medicine, R&D | Employee Stock Options (Right to Buy) | Derivative | Feb 17, 2026 | Exercise/Conversion | 29,927 | $0.00 | $0.00 | 59,854 | Direct | โ | View Details |